NO20082133L - Immunoglobulin-fusjonsproteinformuleringer - Google Patents

Immunoglobulin-fusjonsproteinformuleringer

Info

Publication number
NO20082133L
NO20082133L NO20082133A NO20082133A NO20082133L NO 20082133 L NO20082133 L NO 20082133L NO 20082133 A NO20082133 A NO 20082133A NO 20082133 A NO20082133 A NO 20082133A NO 20082133 L NO20082133 L NO 20082133L
Authority
NO
Norway
Prior art keywords
fusion protein
compositions
immunoglobulin fusion
protein formulations
lyophilized
Prior art date
Application number
NO20082133A
Other languages
English (en)
Inventor
Li Li
Nicholas W Warne
Anthony Barry
Thomas Crowley
Daniel Dixon
Jennifer Juneau
Ajaj Kumar
Nicholas Luksha
Michael Shamashkin
Erin Soley
Chandra A Webb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20082133L publication Critical patent/NO20082133L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SAMMENDRAG Det beskrives blandinger av Ig-fusjonsproteiner, spesielt blandinger som inneholder et Ig-fusjonsprotein, et fyllmiddel, et disakkarid, et overflateaktivt middel og en buffer. I henhold til ett aspekt er disse blandingene stabile under langtidslagring eller i det minste én fryse/tine-syklus. Videre beskrives fremgangsmåter for fremstilling av Ig-fusjonsproteinblandingene. I henhold til ett aspekt er blandingene lyofilisert. I henhold til et annet aspekt er blandingene lyofilisert etter en fremgangsmåte som innbefatter et kjøletrinn.
NO20082133A 2005-11-22 2008-05-07 Immunoglobulin-fusjonsproteinformuleringer NO20082133L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73927105P 2005-11-22 2005-11-22
PCT/US2006/045059 WO2007062040A1 (en) 2005-11-22 2006-11-21 Immunoglobulin fusion protein formulations

Publications (1)

Publication Number Publication Date
NO20082133L true NO20082133L (no) 2008-06-16

Family

ID=37781927

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082133A NO20082133L (no) 2005-11-22 2008-05-07 Immunoglobulin-fusjonsproteinformuleringer

Country Status (14)

Country Link
US (2) US20070237758A1 (no)
EP (1) EP1951305A1 (no)
JP (1) JP2009516692A (no)
KR (1) KR20080071192A (no)
CN (1) CN101312744A (no)
AU (1) AU2006318583A1 (no)
BR (1) BRPI0618893A2 (no)
CA (1) CA2630115A1 (no)
CR (1) CR10012A (no)
EC (1) ECSP088459A (no)
NO (1) NO20082133L (no)
RU (1) RU2008118166A (no)
SV (1) SV2009002911A (no)
WO (1) WO2007062040A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2612937C (en) * 2005-07-22 2014-05-06 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CL2008000058A1 (es) * 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
WO2008101179A2 (en) * 2007-02-16 2008-08-21 Wyeth Use of sucrose to suppress mannitol-induced protein aggregation
ES2436779T3 (es) * 2007-11-12 2014-01-07 Ares Trading S.A. Formulaciones para proteínas de fusión TACI-inmunoglobulina
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
EP2442798A4 (en) * 2009-06-18 2013-03-13 Wyeth Llc LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS
CN101693016B (zh) * 2009-11-02 2012-07-25 北京美福源生物医药科技有限公司 通用的注射用重组人血清白蛋白融合蛋白制剂配方
JP2013510158A (ja) 2009-11-03 2013-03-21 グリフオルス・セラピユーテイクス・インコーポレーテツド α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
WO2011066291A2 (en) * 2009-11-24 2011-06-03 Talecris Biotherapeutics, Inc. Lyophilization methods, compositions, and kits
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
GB201513010D0 (en) 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
MA42657A (fr) 2015-08-18 2018-06-27 Regeneron Pharma Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CN110607554B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备药物或药物中间体单晶或无定型物的方法
CN111195349B (zh) * 2018-11-16 2023-02-24 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干粉制剂
BR112021012675A2 (pt) * 2019-01-06 2021-09-28 Endo Global Aesthetics Limited Formulação, formulação liofilizada, formulação reconstituída e kit
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
EP1516628B1 (en) * 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP3900664B2 (ja) * 1997-09-26 2007-04-04 株式会社ニコン 顕微鏡
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
BR0008405B1 (pt) * 1999-02-22 2014-04-22 Baxter Int Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
AU2003219958B2 (en) * 2002-02-27 2006-01-05 Immunex Corporation Polypeptide formulation
EP1720519A1 (en) * 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization

Also Published As

Publication number Publication date
BRPI0618893A2 (pt) 2011-09-13
EP1951305A1 (en) 2008-08-06
AU2006318583A1 (en) 2007-05-31
JP2009516692A (ja) 2009-04-23
CA2630115A1 (en) 2007-05-31
KR20080071192A (ko) 2008-08-01
US20110033464A1 (en) 2011-02-10
ECSP088459A (es) 2008-06-30
RU2008118166A (ru) 2009-12-27
CN101312744A (zh) 2008-11-26
WO2007062040A1 (en) 2007-05-31
US20070237758A1 (en) 2007-10-11
CR10012A (es) 2008-07-29
SV2009002911A (es) 2009-03-04

Similar Documents

Publication Publication Date Title
NO20082133L (no) Immunoglobulin-fusjonsproteinformuleringer
NO20065084L (no) Interferon-alfa polypeptider og konjugater
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
NO20052363L (no) Interferon-alfa polypeptider og konjugater
NO20074278L (no) Tigecyklinblandinger og fremgangsmater for fremstilling
DK1422237T3 (da) Fremgangsmåder til rekombinant frembringelse af antifusogene peptider
RU2009149604A (ru) Способ предоставления устойчивого к температуре миорелаксанта на основе нейротоксичного компонента ботулинического токсина в твердой форме
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
DK1856159T3 (da) Kimære, rekombinante antigener af Toxoplasma gondii
DE602007005634D1 (de) Variante foki-spaltungshälften-domänen
WO2007079185A3 (en) Improved composition for collecting and preserving placental stem cells and methods of using the composition
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
CO6612194A2 (es) Métodos de purificaciñon de adamts 13 y otras proteinas recombinantes y sus composiciones
NO20062315L (no) Minimal DNA-sekvens som virker som en kromatinisolator og dets anvendelse i proteinekspresjon
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
WO2006019876A3 (en) Production of fusion proteins by cell-free protein synthesis
AR054599A1 (es) Proteccion de la proteina krp mutante negativa dominante contra una inhibicion activa del complejo cdk -ciclina por la krp de tipo salvaje
WO2007008647A3 (en) Diagnosing and grading gliomas using a proteomics approach
BRPI0820177B8 (pt) métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas
WO2006039396A3 (en) Non-embedded tissue microarray technology for protein and nucleic acid analyses
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
ES2418459R1 (es) Relacionando agregacion proteica con supervivencia de levadura
WO2007008697A3 (en) Compositions and methods for refolding of denatured proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application